|
Detection of minimal residual disease (MRD) in colorectal cancer (CRC) patients UICC stage II/III by ultra-deep sequencing of cfDNA from post-surgery plasma. |
|
|
Employment - Signature Diagnostics |
Stock and Other Ownership Interests - Roche |
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Roche |
|
|
Employment - Signature Diagnostics AG |
|
|
Employment - BeiGene (I); Genentech |
Stock and Other Ownership Interests - BeiGene (I); Genentech/Roche |
|
|
Employment - Roche Molecular Diagnostics |
Stock and Other Ownership Interests - Roche Molecular Diagnostics |
Patents, Royalties, Other Intellectual Property - patent pending with Roche |
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Roche |
|
|
|
Stock and Other Ownership Interests - Clovis Oncology; Editas Medicine; Exact Sciences; Johnson & Johnson; Roche |